Navigation Links
Targeted toxin active in platinum-resistant ovarian cancers
Date:4/6/2013

WASHINGTON -- A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research. The findings (abstract LB-290) will be discussed at a press conference on Saturday, April 06, 2013, 1:00 p.m., ET, in Room 153, in the Washington Convention Center and later at an oral presentation on Tuesday, April 09, 2013, 4:00 p.m. to 4:20 p.m. in room 146, in the Washington Convention Center.

Joyce Liu, MD, MPH, first author of the study, said that among 29 patients who received the antibody-drug conjugate at what was found to be the maximum tolerated dose, there was one complete response and four partial responses. "In addition, there were additional patients with prolonged stable disease who were able to stay on treatment," said Liu, of the gynecologic oncology treatment center at Dana-Farber.

The responses all occurred in patients whose tumors had high expression of the MUC16 protein to which the drug is targeted. Known as DMUC5754A, the drug conjugate consists of an antibody, which recognizes the MUC16 protein expressed by ovarian cancer cells, fused to a toxin, MMAE, which prevents cancer cells from dividing. Targeting the drug conjugate specifically to ovarian cancer cells reduced adverse effects of the toxin on healthy tissues and organs, said Liu. She called the safety profile "encouraging." Most common adverse effects were fatigue, nausea, and vomiting. This phase 1 multicenter trial is the first use in humans of DMUC5754A, and the responses, which Liu called "a nice sign of activity in a very challenging type of ovarian cancer to treat," merit further testing in a phase II trial, which is being planned. "If the activity of this drug is confirmed in additional trials, this will represent a novel type of therapy for ovarian cancer," Liu said.


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. The future of personalized and targeted cancer therapy
2. Medicaid Fraud in New York Targeted by New House Report
3. Targeted Equine Nutrition Launches New Website For Horse Lovers
4. Banning food ads targeted at kids
5. Study finds tiny, targeted drug particles may be effective in treating chronic diseases
6. Blood Test Plus Targeted Care May Stop Heart Failure Before It Starts
7. Medical Advertising Agency bryantBROWN Healthcare Introduces Targeted Point-of-Care Promotions to Help Law Firms Connect More Directly With Patients and Caregivers
8. Tuberculosis and neglected diseases targeted by new center
9. Lancet Oncology: Long-term side-effects of targeted therapies in pediatric cancer patients
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Quick Weight Loss for Women of All Ages With Targeted Diet Plan
11. High Complexity Laboratory Testing Supports New Targeted Therapies for Leukemias and Lymphomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... Sodium determination is consistently becoming more ... expert user knowledge. In a live webinar on April 11th and October 3rd, ... accurate, determination of sodium. , It has long been known that too much ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new ... invalid because it does not obey the rules Congress has directed the CBO to ... which the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Invivotek, LLC, a Genesis Biotechnology Group ® ... pharmacology contract research organization (CRO), announced the completion of ... preclinical research facility in Hamilton, New Jersey ... energy source to reduce costs and lessen the CRO ... Solar Farm follows Invivotek,s recent expansion from a 19,712 ...
(Date:3/24/2017)... -- New England Pediatric Device Consortium (NEPDC) announced Velano ... and in-kind service towards the commercialization of the company,s ... blood draws less traumatic for children could go a ... We,re looking forward to working with Velano Vascular to ... the kids we treat," said Ann-Christine Duhaime , ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants in ... Canada , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ...
Breaking Medicine Technology: